These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 38652045)
1. Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient. Pacak K; Taieb D; Lin FI; Jha A J Clin Endocrinol Metab; 2024 Aug; 109(9):2366-2388. PubMed ID: 38652045 [TBL] [Abstract][Full Text] [Related]
2. High-Specific-Activity- Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867 [TBL] [Abstract][Full Text] [Related]
3. Parghane RV; Talole S; Basu S Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123 [TBL] [Abstract][Full Text] [Related]
4. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370 [TBL] [Abstract][Full Text] [Related]
5. Radio theranostics in paragangliomas and pheochromocytomas. Prado Wohlwend S; Bello Arques P; Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(4):500017. PubMed ID: 38735639 [TBL] [Abstract][Full Text] [Related]
6. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382 [TBL] [Abstract][Full Text] [Related]
7. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242 [TBL] [Abstract][Full Text] [Related]
8. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy. Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195 [TBL] [Abstract][Full Text] [Related]
9. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072 [TBL] [Abstract][Full Text] [Related]
10. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Pandit-Taskar N; Chen CC Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501 [TBL] [Abstract][Full Text] [Related]
11. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma. Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668 [TBL] [Abstract][Full Text] [Related]
12. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma. Jungels C; Karfis I Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336 [TBL] [Abstract][Full Text] [Related]
13. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ; Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026 [TBL] [Abstract][Full Text] [Related]
14. The utility of Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042 [TBL] [Abstract][Full Text] [Related]
15. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Taïeb D; Jha A; Treglia G; Pacak K Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209 [TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial for [ Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983 [TBL] [Abstract][Full Text] [Related]
17. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy. Makis W; McCann K; Bryanton M; McEwan AJ Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563 [TBL] [Abstract][Full Text] [Related]
18. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368 [TBL] [Abstract][Full Text] [Related]
20. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]